Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
(Unit: KRW in millions)
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in millions)
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating profit | -2,580 | -2,908 | -2,849 |
| Other gains | 2 | 3 | 75 |
| Other losses | 2,882 | 1,483 | 3,771 |
| Finance costs | 1,955 | 5,147 | 3,953 |
| Finance income | 4,962 | 872 | 5,451 |
| Cost Of Sales | 2,967 | 3,853 | 4,743 |
| Net profit | -2,454 | -8,663 | -5,047 |
| Sales | 8,493 | 10,521 | 11,427 |
(Unit: KRW in millions)
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in millions)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Total Assets | 27,703 | 23,097 | 47,193 |
| Current Assets | 14,445 | 8,527 | 19,234 |
| Non-current Assets | 13,258 | 14,570 | 27,959 |
| Capital surplus | 27,257 | 27,257 | 37,428 |
| Total equity | 13,932 | 6,377 | 15,226 |
| Share capital | 4,570 | 4,570 | 8,180 |
| Retained earnings | -15,896 | -24,559 | -29,606 |
| Current liabilities | 10,238 | 12,558 | 23,635 |
| Total liabilities | 13,771 | 16,721 | 31,967 |
| Non-Current liabilities | 3,533 | 4,163 | 8,331 |